Antisense Oligonucleotide Therapeutics Pipeline Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antisense Oligonucleotide Therapeutics – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Antisense Oligonucleotide Therapeutics – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Antisense Oligonucleotide Therapeutics: Overview

Antisense oligonucleotide (ASOs) are small-sized single-stranded nucleic acids that offer advantages over siRNAs in terms of targeting both nuclear and cytoplasmic located lncRNAs. Antisense oligonucleotide-based therapeutics involves downregulation of gene expression.

Antisense oligonucleotides (AOs) are a class of synthetic nucleic acid molecules that are capable of regulating gene expression through binding to premature or mature messenger RNA (mRNA) targets. Antisense oligonucleotides (ASOs), known as genetic materials, are promising agents used in the regulation of unsuitable expression of genes in pathological situations by the specific inhibition of expression of their mRNA targets.

By capitalizing “antisense” DNA approach, the overexpressed proteins can be blocked in several diseases such as cancer, neurological diseases, cardiovascular diseases, inflammation and autoimmune diseases, infectious diseases, etc. ASOs are emerging as a class of therapeutics with high potential to treat diseases affecting the CNS.

Antisense Oligonucleotide Therapeutics Emerging Drugs Chapters

This segment of the Antisense Oligonucleotide Therapeutics report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Antisense Oligonucleotide Therapeutics Emerging Drugs

Cobitolimod: InDex Pharmaceuticals

Cobitolimod is a Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod is a DNA-based ImmunoModulatory Sequence (DIMS) that is administered locally inside the large intestine, where it binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells.

Cobitolimod is a first in class treatment that can provide a local anti-inflammatory effect, which can lead to healing of the mucosa and improvement of clinical symptoms. Cobitolimod is has a very limited systemic absorption. US Food and Drug Administration (FDA) has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Prexigebersen: Bio-Path Holdings

Prexigebersen (previously BP 100-1-01) is a neutral-charge, liposomal-delivered antisense cancer drug. It is designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2). Bio-Path is currently evaluating prexigebersen in Phase II program for the treatment of acute myeloid leukemia (AML). Prexigebersen has received orphan drug designation from the FDA and from the European Medicines Agency for AML.

Major Players working on Antisense Oligonucleotide Therapeutics

There are approx. 15+ key companies which are developing the Antisense Oligonucleotide Therapeutics. The companies which have their Antisense Oligonucleotide Therapeutics drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Key Players

• InDex Pharmaceuticals
• Bio-Path Holdings
• Akcea Therapeutics
• Ionis Pharmaceuticals
• AstraZeneca
• Gene Signal
• Chamishi Therapeutics
• NeuBase Therapeutics

Key Products

• Cobitolimod
• Prexigebersen
• Inotersen
• AKCEA APOCIII LRx
• ION 736
• NS-089/NCNP-02
• Aganirsen

Research Programme

• NT0100

Key Topics Covered:

Introduction

Executive Summary

Antisense Oligonucleotide Therapeutics: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Antisense Oligonucleotide Therapeutics – Analytical Perspective

In-depth Commercial Assessment

• Antisense Oligonucleotide Therapeutics companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Antisense Oligonucleotide Therapeutics Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Cobitolimod: InDex Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Prexigebersen: Bio-Path Holdings

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

ION 736: Ionis Pharmaceuticals/AstraZeneca

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

NT0100: NeuBase Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Antisense Oligonucleotide Therapeutics Key Companies

Antisense Oligonucleotide Therapeutics Key Products

Antisense Oligonucleotide Therapeutics – Unmet Needs

Antisense Oligonucleotide Therapeutics – Market Drivers and Barriers

Antisense Oligonucleotide Therapeutics – Future Perspectives and Conclusion

Antisense Oligonucleotide Therapeutics Analyst Views

Antisense Oligonucleotide Therapeutics Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6cg50c

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900